Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity drug shows promise in early trial

NCT ID NCT06313528

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage study tested a new drug called LY3437943 in 85 people with obesity. Participants received either the drug or a placebo, and researchers measured how many calories they ate and how their bodies used energy. The goal was to see if the drug could help control appetite and metabolism under a reduced-calorie diet.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LY3437943
What this could lead to
If successful, this could point toward a new treatment option for obesity that helps control appetite and energy use.
What could go wrong
This is an early Phase 1 study with only 85 participants, so results may not apply broadly. The drug may not show meaningful benefits or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

85 people

The number who actually took part.

Started

Mar 2024

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BMI greater than 30 kg/m2 * History of at least 1 self-reported unsuccessful dietary effort to reduce body weight Exclusion Criteria: * Change in body weight of greater than 5 kg (11 pounds) within 3 months prior to start of study * Any of the following treatments for obesity within 1 year prior, or plan to undergo any of these during the study period: liposuction, cryolipolysis, or abdominoplasty * Prior or planned bariatric or gastric sleeve surgery, endoscopic therapy, or device-based therapy for obesity * Type 1 or Type 2 Diabetes, history of ketoacidosis, or hyperosmolar state * Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome Type 2 * Acute or chronic hepatitis * Had within 90 days prior: acute myocardial infarction, cerebrovascular accident (stroke), coronary artery revascularization, hospitalization for unstable angina, or hospitalization due to congestive heart failure * History of active or unstable major depressive disorder or other severe psychiatric disorder within 2 years prior * History of chronic or acute pancreatitis * Blood transfusion or severe blood loss within the last 3 months or hemoglobinopathy, hemolytic anemia, sickle cell anemia * Clinically significant multiple or severe drug allergies * Started treatment with or changed dose within 12 months prior any medications that are associated with significant weight gain * History of substance use disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • AdventHealth Orlando

    Orlando, Florida, 32804, United States

  • Columbia University Irving Medical Center

    New York, New York, 10032, United States

  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana, 70808, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.